Regenxbio names Olivier Danos chief scientific officer
Dr. Danos joins Regenxbio from Biogen Inc., where he was Senior Vice President, Cell and Gene Therapy.
At Biogen, Dr. Danos led company efforts dedicated to identifying and developing new technologies for gene transfer and genome engineering.
He also co-founded and is an executive member of the board of directors of Lysogene, a NAV Technology Licensee.
Prior to Biogen, Dr. Danos served as Senior Vice President, Molecular Medicine, Synthetic Biology and Gene Regulation at Kadmon Pharmaceuticals.
Earlier in his career, Dr. Danos was Director of the Gene Therapy Consortium of the University College of London, Scientific Director at Genethon and Senior Director of Research at Somatix Therapy Corporation.
He has directed research focused on gene therapy at the Necker - Enfants Malades Hospital in Paris, the French National Centre for Scientific Research and the Pasteur Institute in Paris.
Dr. Danos received a Ph.D. in Biology at the University of Paris Diderot and the Pasteur Institute, and a Master in Science in Genetics and Mathematics from the University of Paris Orsay.
He is a founding member of the European Society of Gene and Cell Therapy. ■
LATEST MOVES FROM Maryland
- Global Medical REIT president Jeffrey Busch to take CEO role
- U.S. Silica adds Diane K. Duren to board
- Robert Kiernan to join Global Medical REIT as CFO
- Under Armour appoints Patrik Frisk as COO
- Osiris Therapeutics appoints Linda Palczuk as CEO
More inside POST
Tyson Foods Q3 profit down Earnings